Setipiprant
CAS No. 866460-33-5
Setipiprant( ACT-129968 | ACT 129968 | KYTH 105 | Setipiprant )
Catalog No. M19195 CAS No. 866460-33-5
Setipiprant is an orally available, selective CRTH2 antagonist (IC50: 6.0 nM). CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 10MG | 29 | In Stock |
|
| 25MG | 46 | In Stock |
|
| 50MG | 72 | In Stock |
|
| 100MG | 114 | In Stock |
|
| 200MG | 184 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSetipiprant
-
NoteResearch use only, not for human use.
-
Brief DescriptionSetipiprant is an orally available, selective CRTH2 antagonist (IC50: 6.0 nM). CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2).
-
DescriptionSetipiprant is an orally available, selective CRTH2 antagonist (IC50: 6.0 nM). CRTH2 is a G protein-coupled receptor for prostaglandin (PGD2). PGD2 is produced by the mast cells and is a key mediator in various inflammatory diseases, including allergy and asthma. Binding of PGD2 to CRTH2, which are expressed on the surface of blood-borne cells, induces chemotaxis of Th2 cells, basophils, and eosinophils, and stimulates cytokine release from these cells.(In Vitro):Setipiprant (0-10 μM; 90 min) interacts with hCRTH2 receptor in the absence and presence of Human Serum Albumin (HSA) in the assay buffer with IC50 values of 6 and 340 nM, respectively.Setipiprant (0-10 μM; 5-20 min) inhibits hCRTH2 receptor based intracellular calcium liberation, intracellular cAMP and shape change of human eosinophils with IC50 values of 30, 80 and 235 nM, respectively.Setipiprant (0-10 μM) inhibits prostanoid receptors hDP1, hEP2 and hEP4 with IC50 values of 1290, 2600 and >10000 nM, respectively.(In Vivo):Pharmacokinetic Properties of Setipiprant in Rats and Dogs.
-
In VitroSetipiprant (0-10 μM; 90 min) interacts with hCRTH2 receptor in the absence and presence ofHuman Serum Albumin (HSA) in the assay buffer with IC50 values of 6 and 340 nM, respectively.Setipiprant (0-10 μM; 5-20 min) inhibits hCRTH2 receptor based intracellular calcium liberation, intracellular cAMP and shape change of human eosinophils with IC50 values of 30, 80 and 235 nM, respectively.Setipiprant (0-10 μM) inhibits prostanoid receptors hDP1, hEP2 and hEP4 with IC50 values of 1290, 2600 and >10000 nM, respectively.
-
In Vivo——
-
SynonymsACT-129968 | ACT 129968 | KYTH 105 | Setipiprant
-
PathwayOthers
-
TargetOther Targets
-
RecptorCRTh2
-
Research AreaInflammation/Immunology
-
Indication——
Chemical Information
-
CAS Number866460-33-5
-
Formula Weight402.42
-
Molecular FormulaC24H19FN2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 36 mg/mL; 89.46 mM
-
SMILESC1CN(CC2=C1N(C3=C2C=C(C=C3)F)CC(=O)O)C(=O)C4=CC=CC5=CC=CC=C54
-
Chemical Name2-(2-(1-naphthoyl)-8-fluoro-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)acetic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Diamant Z., et al. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics. Clin Exp Allergy. 2014 Aug;44(8):1044-52.
molnova catalog
related products
-
(+)-Lariciresinol 4-...
(+)-Lariciresinol 4'-O-beta-D-Glucopyranosyl-(1->3)-beta-D-glucopyranoside is a natural product for research related to life sciences.
-
R-E-D-V
REDV is the minimal active sequence within the CS5 site of the alternatively spliced type III connecting segment (IIICS) region of fibronectin. REDV can mediate adhesion to the IIICS region of plasma fibronectin by binding the integrin alpha 4 beta 1(α4β1). REDV can be used for the research of cell adhesion.
-
Compound V007-6018
Compound V007-6018 is a pharmaceutical compound used for drug screening.
Cart
sales@molnova.com